{"id":"atv-r-tdf-ftc-or-drv-r-tdf-ftc","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Diarrhea"},{"rate":"5-20","effect":"Nausea"},{"rate":"5-15","effect":"Headache"},{"rate":"5-10","effect":"Rash"},{"rate":"10-20","effect":"Elevated bilirubin (atazanavir)"},{"rate":"1-5","effect":"Renal impairment (tenofovir-related)"},{"rate":"variable","effect":"Bone density loss"}]},"_chembl":{"chemblId":"CHEMBL25033","moleculeType":"Small molecule","molecularWeight":"247.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ATV/r (atazanavir/ritonavir) or DRV/r (darunavir/ritonavir) are protease inhibitors that prevent HIV protease from cleaving viral polyproteins, while TDF/FTC (tenofovir/emtricitabine) are nucleoside reverse transcriptase inhibitors that block reverse transcriptase activity. Ritonavir acts as a pharmacokinetic booster, increasing protease inhibitor levels. Together, these agents target two critical steps in the HIV replication cycle.","oneSentence":"This is a combination antiretroviral regimen that uses protease inhibitors (boosted with ritonavir) plus nucleoside reverse transcriptase inhibitors to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:01.855Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection (treatment-naïve or treatment-experienced patients)"}]},"trialDetails":[{"nctId":"NCT02016924","phase":"PHASE2, PHASE3","title":"Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2014-01-16","conditions":"Acquired Immune Deficiency Syndrome (AIDS), HIV Infections","enrollment":133},{"nctId":"NCT06337032","phase":"PHASE4","title":"A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-27","conditions":"HIV-1-infection","enrollment":350},{"nctId":"NCT02284035","phase":"PHASE3","title":"Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine","status":"COMPLETED","sponsor":"Juan A. Arnaiz","startDate":"2015-09-27","conditions":"AIDS","enrollment":75},{"nctId":"NCT02616029","phase":"PHASE3","title":"Study to Evaluate Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Fixed Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adults Harboring the Archived Isolated NRTI Resistance Mutation M184V/M184I","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-17","conditions":"HIV-1 Infection","enrollment":66},{"nctId":"NCT02121795","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-05-06","conditions":"HIV-1 Infection","enrollment":668},{"nctId":"NCT02616783","phase":"PHASE3","title":"Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"HIV-1 Infection","enrollment":167},{"nctId":"NCT02469246","phase":"PHASE3","title":"Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-29","conditions":"HIV-1 Infection","enrollment":567},{"nctId":"NCT01641367","phase":"PHASE4","title":"A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2013-02-22","conditions":"HIV-1 Infection","enrollment":545},{"nctId":"NCT02605954","phase":"PHASE3","title":"Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-18","conditions":"HIV-1 Infection","enrollment":275},{"nctId":"NCT00851799","phase":"","title":"Impact of Antiretroviral Therapy on Metabolic, Skeletal, and Cardiovascular Parameters","status":"COMPLETED","sponsor":"Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections","startDate":"2009-06","conditions":"HIV Infection","enrollment":334}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":70,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PI-Based Regimens"],"phase":"phase_3","status":"active","brandName":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","genericName":"ATV/r + TDF/FTC or DRV/r + TDF/FTC","companyName":"Juan A. Arnaiz","companyId":"juan-a-arnaiz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination antiretroviral regimen that uses protease inhibitors (boosted with ritonavir) plus nucleoside reverse transcriptase inhibitors to suppress HIV replication by blocking viral protease and reverse transcriptase enzymes. Used for HIV-1 infection (treatment-naïve or treatment-experienced patients).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}